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ABSTRACT
Background: Preliminary data have shown that the FirebirdTM 
and the Cypher® stents have similar safety and efficacy pro-
files. However, to date, no study has evaluated percutaneous 
coronary intervention (PCI) with the FirebirdTM stent in diabetic 
patients. Methods: The performance of the FirebirdTM stent 
in diabetic patients with multivessel coronary artery disease 
(CAD) (n  =  100) was compared with that of the Cypher® 
stent using historical data from the ARTS-II study (n = 159). 
One-year major adverse cardiovascular events (MACE) were 
compared. Results: Most of the patients in the FirebirdTM 
group were male (65%), with a mean age of 63.3 ± 10.4 
years, and 5% were on insulin. Stable coronary syndrome 
was prevalent (60%), and 45% of patients had three-vessel 
CAD with preserved ventricular function (56.6 ± 13.7%). In 
patients with three-vessel CAD, 135 lesions were treated with 
three or more stents in 78% of cases and with two stents in 
the remainder. In patients with two-vessel CAD, 110 lesions 
were treated with two or more stents in 80% of the cases and 
with one stent in the remainder. The one-year incidence of 
MACE with the FirebirdTM stent was 21%. Mortality occurred 
in 3% of the patients, myocardial infarction in 2%, and a 
new revascularisation procedure in 18%, predominantly a 
new PCI (14% of cases). Comparison with the Cypher® group 
did not show differences for any of the evaluated endpoints. 
Conclusions: In the present study, the use of the FirebirdTM 
stent showed similar results to those of the patients in the 
ARTS-II study, demonstrating its suitability for use in the 
complex scenario of diabetic patients with multivessel CAD.
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RESUMO
Desempenho do Stent Farmacológico Firebird™ em 
Diabéticos Portadores de Doença Coronária Multiarterial
Introdução: Dados preliminares têm demonstrado que o perfil 
de segurança e eficácia do stent FirebirdTM é semelhante ao do 
stent Cypher®. No entanto, até o presente momento, ne nhum 
estudo avaliou a intervenção coronária percutânea (ICP) com o 
FirebirdTM em diabéticos. Métodos: Comparamos, em diabéticos 
portadores de doença arterial coronária (DAC) multiarterial, o 
desempenho do Firebird™ (n = 100) ao do Cypher®, utilizando 
os dados históricos do estudo ARTS-II (n = 159). Foram com-
parados os eventos cardiovasculares adversos maiores (ECAM) 
em um ano. Resultados: A maioria dos pacientes do grupo 
FirebirdTM era do sexo masculino (65%), com média de idade de 
63,3 ± 10,4 anos e 5% estavam em uso de insulina. Predomi-
naram os quadros clínicos estáveis (60%), 45% eram portado-
res de DAC triarterial e a função ventricular era preservada 
(56,6 ± 13,7%). Nos pacientes com DAC triarterial, foram 
tratadas 135 lesões, com 3 ou mais stents em 78% dos casos 
e 2 stents nos demais. Nos pacientes com DAC biarterial, 
foram tratadas 110 lesões com 2 ou mais stents em 80% 
dos casos e 1 stent nos demais. A incidência de ECAM em 
um ano do Firebird™ foi de 21%, óbito ocorreu em 3% dos 
pacientes, infarto do miocárdio em 2%, e novo procedimento 
de revascularização miocárdica em 18%, predominantemente 
à custa de nova ICP em 14% dos casos. A comparação com 
o grupo Cypher® não mostrou diferenças para nenhum dos 
desfechos avaliados. Conclusões: Em nosso estudo, o uso do 
stent Firebird™ apresentou resultados similares aos dos pacientes 
do estudo ARTS-II, o que o torna atrativo para ser utilizado 
no complexo cenário de pacientes diabéticos portadores de 
DAC multiarterial.
DESCRITORES: Doença das coronárias. Angioplastia. Stents 
far ma cológicos. Diabetes mellitus.
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T he efficacy of drug-eluting stents in reducing the need for target-lesion revascularisation and adver - se cardiovascular events compared with bare-
metal stents, especially in diabetic patients, has been 
esta blished.1–3
The FirebirdTM drug-eluting stent (Microport Co., 
Ltd. – Qinghai, China) has been approved for clinical 
use in China since 2005, and 350,000 units have been 
used worldwide.4 This stent has a thin stainless steel 
strut platform with an ethylene vinyl acetate copolymer 
coating that releases sirolimus. Preliminary data have 
demonstrated safety and efficacy profiles similar to the 
first-generation sirolimus-eluting stent Cypher® (Cordis 
Cardiology – Miami Lakes, USA).5 However, to date, no 
study has evaluated the performance of the Firebird™ 
stent in diabetic patients.
The objective of the present study was to evaluate 
the performance of the FirebirdTM stent in patients with 
diabetes mellitus and multi-vessel coronary artery disease 
(CAD), and to compare it with the Cypher® stent using 
the historic diabetic data of the Arterial Revascularisa-
tion Therapies Study (ARTS-II).6
METHODS
Patients
From January of 2006 to December of 2010, 354 
patients were treated in this service with the FirebirdTM 
stent, 100 (28.2%) of whom had diabetes mellitus and 
multi-vessel coronary artery disease and were selected 
for this analysis. Patients whose initial presentation 
included ST-elevation myocardial infarction or percu-
taneous coronary intervention (PCI) in saphenous grafts 
were excluded. This group was compared with the 
historic data of 159 diabetic patients with multivessel 
disease from the ARTS-II study who were treated with 
the Cypher® stent.
The current study followed the Helsinki Declara-
tion regarding human studies, and all patients signed 
an informed consent.
The stent
The drug-eluting FirebirdTM stent combines a fine 
(0.0040 inches) stainless steel (316  L) strut platform 
with open cells and an N connection in a design that 
incorporates larger and smaller waves and an expansible 
balloon. It is coated with an ethylene vinyl acetate 
copolymer matrix that releases a dose of 9  µg/mm2 
of sirolimus.
Percutaneous coronary intervention
Percutaneous coronary interventions were performed 
according to current guidelines,7 and the final procedure 
strategy was at the discretion of the surgeon.
During the procedure, 70  IU/kg to 100  IU/kg of 
non-fractionated heparin were administered, and the 
use of glycoprotein IIb/IIIa inhibitors was left to the 
discretion of the surgeon. Pre-dilation was not manda-
tory, and post-dilation was recommended in the case 
of residual stenosis >  20% by a visual estimate.
The dual anti-platelet therapy consisted of acetyl-
salicylic acid (100 g/day) and clopidogrel (75 mg/day). 
Clopidogrel should have been started at least 24 hours 
before the procedure, at a loading dose of 300 mg (or 
600 mg if PCI < 24 hours). After the PCI, therapy with 
acetylsalicylic acid was continued indefinitely, with 
clopidogrel therapy for at least 12 months.
Outcomes and clinical follow-up
The primary outcome of the study was the develop-
ment of major adverse cardiac events (MACE) during 
the 12-month follow-up. MACE was defined as death, 
non-fatal acute myocardial infarction, or the need for 
new revascularisation. All deaths were considered 
to be cardiac in origin unless a non-cardiac cause could 
be clearly established by clinical and/or pathological 
studies. The diagnosis of acute myocardial infarction 
was based on the development of new pathologic Q 
waves in more than two contiguous electrocardiographic 
leads and/or elevation of the isoenzyme CK-MB over 
three times the upper normal limit after the procedure 
during the index hospitalisation, or over two times the 
upper normal limit after hospital discharge. All revascu-
larisations, surgical or percutaneous, were considered.
A clinical follow-up was performed 12 months after 
the procedure, consisting of a phone contact according 
to a predefined institutional protocol.
Statistical analysis
Categorical variables were described as percent-
ages and were compared using the chi-squared test or 
Fisher exact test. Continuous variables were described 
as means and standard deviations and were compared 
using the Student’s test. One-year clinical events were 
compared with the diabetic subgroup of the ARTS-II 
study. A value of P < 0.05 was considered statistically 
significant.
RESULTS
In this study, 100 patients treated with the FirebirdTM 
stent were compared with 159 diabetic patients with 
multivessel disease from the ARTS-II study treated with 
the Cypher® stent.
Clinical and anatomical characteristics of the patients 
are summarised in Table 1, and no significant differences 
were observed. Most patients in the FirebirdTM group 
were male (65%), with a mean age of 63.3 ± 10.4 years, 
and 5% were on insulin. On clinical presentation, stable 
patients predominated (60%); 45% had three-vessel 
Osterne et al.
Firebird™ Drug-eluting Stent in Diabetic Patients with Multivessel Disease
Rev Bras Cardiol Invasiva. 
2012;20(1):58-62
60
disease and 55% presented two-vessel disease, and 
ventricular function was preserved (56.6  ±  13.7%). In 
patients with three-vessel disease, 135 lesions were 
treated with three or more stents in 78% of the cases 
and with two stents in the remainder (22%). In patients 
with two-vessel disease, 110 lesions were treated with 
two or more stents in 80% of cases and with one 
stent in the remaining 20%. The one-year incidence of 
MACE in the FirebirdTM group was 21%: 3% mortality 
2% acute myocardial infarction, and new myocardial 
revascularisation was performed in 18% predominantly 
through a new PCI in 14% of cases. In this group, stroke 
was not observed. Compared with the Cypher® group, 
significant differences in the outcomes were not observed 
(Table 2).
DISCUSSION
In the present study, it was demonstrated that the 
one-year clinical results of the FirebirdTM stent in a high 
complexity clinical and anatomical scenario, i.e., in 
patients with diabetes mellitus and multivessel coro-
nary artery disease, were similar to the results of the 
historic data of the subgroup of diabetic patients with 
multivessel coronary artery disease from the ARTS-II 
study treated with the Cypher® stent.
Drug-eluting stents significantly reduce late lu-
minal loss and angiographic restenosis as well as 
the need for new revascularisation, when compared 
with bare-metal stents. Specifically, the Cypher® stent 
has demonstrated its efficacy in diabetic patients in 
randomised clinical studies and large registries.1,8–11 
TABLE 1 




(n = 159) P
Age, mean ± standard deviation 63.3 ± 10.4 64.5 ± 8.7 0.61
Male gender, % 65 66.7 0.56
Body mass index, kg/m² 27 ± 4.3 28.8 ± 4.5 0.11
Current smoking, % 15 11.9 0.93
Hypertension, % 72 79.9 0.77
Dyslipidaemia, % 75  74.1 0.88
Diabetes on insulin, % 5 4.6 0.76
Prior AMI, % 31 29.6 0.88
Prior angioplasty, % 2 0 0.86
Prior surgery, % 2 1.9 0.81
Clinical presentation, % 0.17
Stable angina 60 53.5
Unstable angina 30 32.1
Silent ischaemia 14 14.5
Ejection fraction, % 56.6 ± 13.7 59.5 ± 11.8 0.66
Lesion type (AHA/ACC), % 0.22
A/B1 30 27
B2/C 70 73
Number of vessels, % 0.88
One-vessel 0 0.6  
Two-vessel 55 49.1  
Three-vessel 45 50.3  
AHA/ACC = American Heart Association/American College of Cardiology; AMI = acute myocardial infarction; n = number of patients.
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Its safety was also demonstrated in several studies, in-
cluding the e-Cypher registry in which 15,157 patients 
(18,295 lesions) treated with the sirolimus-eluting stent 
had acute, subacute, and late thrombosis rates of 0.13%, 
0.56%, and 0.19%, respectively, for a total of 0.88% 
over 12 months. Despite the low thrombosis rates of 
the Cypher® stent, diabetes treated with insulin and the 
treatment of multiple lesions were independent predictors 
of one-year stent thrombosis, along with acute coronary 
syndrome, advanced age, post-procedure TIMI flow < 3, 
and very calcified or occluded lesions.12
The very few studies that have evaluated the 
FirebirdTM stent presented favourable clinical results in 
patients representing the daily clinical practice. The 
prospective and multicentre FIREMAN Registry included 
1,029 consecutive patients with complex lesions, and 
evaluated their clinical evolution over one year. The 
most commonly observed angiographic characteristics 
included long lesions (59.2%), multivessel disease 
(50.4%), and small-calibre vessels (31.6%). Major 
adverse cardiovascular events were observed in 5.1% 
of patients, including cardiac death in 0.6%, non-fatal 
acute myocardial infarction in 1.1%, and target-lesion 
revascularisation in 3.5%. Definitive or probable stent 
thrombosis affected 1.36% of patients. Diabetes, small-
calibre coronary arteries, and chronic occlusions were 
predictors of stent thrombosis.13
Zhang et al.14 investigated the clinical efficacy and 
safety of the FirebirdTM stent over a longer follow-up period. 
This study included 509 consecutive patients, 65.4% of 
whom were treated for off-label indications. The three-
year MACE-free survival was 92.1%. In diabetic patients, 
TABLE 2 








Death, % 3 2.5 1.20 (0.19–5.33)
Stroke, % 0 0 NA
AMI, % 2 0.6 3.33 (0.59–4.98)
QWMI 2 0.6 3.33 (0.59–4.98)
NQWMI 0 0 –
Death/AMI/stroke, % 7 3.1 2.26 (0.61–7.43)
New CABG, % 18 3.1 1.29 (0.17–5.33)
New PCI, % 14 10.1 1.39 (0.20–16.74)
MACE, % 21 15.7 1.34 (0.18–22.33)
AMI = acute myocardial infarction; 95% CI = 95% confidence interval; MACE = major adverse cardiovascular events; CABG = coronary 
artery bypass graft; NQWMI = non-Q wave myocardial infarction; PCI = percutaneous coronary intervention; QWMI = Q-wave myocardial 
infarction; NA = non-applicable.
the MACE rates (13.7% vs. 6.4%; P < 0.05) and need 
for new revascularisation (9.8% vs. 4%; P  <  0.05) were 
higher, and the MACE-free survival (86.4% vs. 93.6%; 
P < 0.05) was lower at the end of this period.
Recently, Xu et al.5 performed the only com-
parison available between the FirebirdTM and Cypher® 
stents. In their study, 3,979 consecutive patients were 
evaluated; 2,274 treated with the FirebirdTM stent and 
1,705 treated with the Cypher® stent, followed-up for 
2 years. The risk ratios for MACE (1.27; 95% confi-
dence interval [95%  CI] 0.90–1.79), mortality (1.22; 
95%  CI 0.57–2.60), myocardial infarction (1.38; 95%   
CI 0.61–2.40), target-lesion revascularisation (1.10; 95% CI 
0.65–1.80), and definitive or probable stent thrombosis 
(1.22; 95% CI 0.57–2.60) did not show significant dif-
ferences after adjustment for 30 variables between the 
groups.
A new version of this stent, the Firebird 2TM, has 
had structural modifications and now has a new cobalt-
chromium platform with a smaller profile, with cell 
connections in S, reducing the shortening of this stent; 
at the same time, its design, with sinuous and uniform 
waves, combines radial strength and flexibility. It also 
has an expandable balloon, and its new polymer is more 
biocompatible and releases sirolimus more rapidly (90% 
within one month). The Firebird 2TM cObalt-Chromium 
alloy sirolimus-elUting Stent (FOCUS) registry15 recruited 
5,084 patients from 83 centres who used the Firebird 
2TM stent and demonstrated, in a six-month follow-up 
of 99.5% of patients, that the development of MACE 
was 1.8%, with death in 0.6%, myocardial infarction in 
0.95%, and the need for new revascularisation in 0.3%. 
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The incidence of stent thrombosis was 0.43% (22/5,058), 
including eight cases of acute, 11 cases of subacute, and 
three cases of late thrombosis, confirming the six-month 
efficacy and safety in patients in daily practice.
The present findings in diabetic patients with mul-
tivessel disease, along with those of other studies that 
demons trated satisfactory results in the in-stent restenosis 
subgroup16 and in patients who represent the national 
clinical practice, expand the knowledge regarding the 
FirebirdTM stent.17,18
Study limitations
This study has several limitations: 1) it was a 
retrospec tive, single centre study; 2) it had a small study 
population; and 3) patients in the FirebirdTM group were 
evaluated predominantly using the clinical information 
obtained by the team or by telephone contact with 
their physicians.
CONCLUSIONS
The present study suggests that the FirebirdTM stent 
has a safety and efficacy profile similar to that of the 
Cypher® stent, and that the FirebirdTM stent is an op-
tion for use in the treatment of the complex scenario 
of diabetic patients with multivessel disease.
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